NCT03945305Recruiting
Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension
Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension: a Randomized, Parallel-controlled Clinical Trial
Source: ClinicalTrials.gov · Last updated 28 Jul 2026
Brief summary (registry, in English)
The purpose of this study is to explore the efficacy and safety of remote ischemic conditioning for essential hypertension in the community population.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- First submitted
- 8 May 2019
- Start date
- 25 Nov 2023
- Primary completion date
- 31 Jul 2026
- Lead sponsor
- Yi Yang
- Diseases
- High blood pressure
- NCT number
- NCT03945305
What you commit to
- Study type: Interventional
- Planned participants: 500
- From 25 Nov 2023 to the primary completion date, 31 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Planned adjustment of antihypertensive drugs within the next 3 weeks;
- Patients being enrolled or having been enrolled in another clinical trial within the 3 months prior to this clinical trial;
Other illness
- Severe hematologic disorders or significant coagulation abnormalities;
- Individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc;
Other
- Blood pressure ≥ 180/110mmHg;
- Pregnant or lactating women;
- Severe hepatic and renal dysfunction;
- Patients unsuitable for enrollment in the clinical trial according to the investigator's discretion.
Who the study is looking for
- Age≥30 years, ≤ 75 years, regardless of sex;
- Patients with a history of essential hypertension and systolic blood pressure (SBP) ≥140 mmHg in three blood pressure measurements performed on separate days within 3 days prior to enrollment.
- Signed and dated informed consent is obtained.
Age in the registry: 30 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| First Hospital of Jilin University Coordinator of this site? Confirm its status | Changchun | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.